Atezolizumab Mouse, Clone: 6B12, GenScript™

Mouse Monoclonal Antibody

Supplier:  Genscript Corporation A0194940

Catalog No. 50-212-0671

Description

Reconstitute the lyophilized antibody with deionized water (or equivalent) to a final concentration of 0.5 mg/mL. Atezolizumab is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1). Atezolizumab blocks the interaction of PD-L1 with programmed cell death protein 1 (PD-1) and CD80 receptors (B7-1Rs). PD-L1 can be highly expressed on certain tumors, which is thought to lead to reduced activation of immune cells (cytotoxic T-cells in particular) that might otherwise recognize and attack the cancer. Inhibition of PD-L1 by atezolizumab can remove this inhibitor effect and thereby engender an anti-tumor response. It is one of several ways to block inhibitory signals related to T-cell activation, a more general strategy known as immune checkpoint inhibition.

Atezolizumab Monoclonal antibody specifically detects Atezolizumab in Chemical samples. It is validated for ELISA

Specifications

• Antigen: Atezolizumab
• Classification: Monoclonal
• Conjugate: Unconjugated
• Gene Alias: Tecentriq
• Immunogen: Atezolizumab
• Quantity: 40 μg
• Primary or Secondary: Primary
• Product Type: Antibody
• Isotype: IgG1 κ

• Applications: ELISA
• Clone: 6B12
• Formulation: PBS with 0.02% sodium azide; pH 7.4
• Host Species: Mouse
• Purification Method: Protein A
• Regulatory Status: RUO
• Content And Storage: -20°C or -80°C if preferred
• Form: Lyophilized
• Target Molecule: Chemical